Lilly’s Prevail taps Jennifer Doudna's spinout Scribe Therapeutics for neuro genetic medicines

Kyle LaHucik

Senior Reporter

Scribe Therapeutics found another partner, this time with Prevail Therapeutics, a subsidiary of Eli Lilly, in a $75 million upfront deal for neuromuscular and neurological …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lilly’s Prevail taps Jennifer Doudna's spinout Scribe Therapeutics for neuro genetic medicines

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Lil­ly’s Pre­vail taps Jen­nifer Doud­na's spin­out Scribe Ther­a­peu­tics for neu­ro ge­net­ic med­i­cines

Senior Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Lilly’s Prevail taps Jennifer Doudna's spinout Scribe Therapeutics for neuro genetic medicines